이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Beijing Strong BiotechnologiesInc 관리

관리 기준 확인 3/4

Beijing Strong BiotechnologiesInc's CEO는 Xi Liu, Mar2011 에 임명되었습니다 의 임기는 13.25 년입니다. 는 CN¥ 1.05B 가치에 해당하는 회사 주식의 11.43% 직접 소유합니다. 1.05B. 경영진과 이사회의 평균 재임 기간은 각각 13.3 년과 5.5 년입니다.

주요 정보

Xi Liu

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	13.5yrs
CEO 소유권	11.5%
경영진 평균 재임 기간	13.5yrs
이사회 평균 재임 기간	5.8yrs

최근 관리 업데이트

Recent updates

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Jul 25

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Jul 03

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

Jun 14

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Mar 21

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Mar 03

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Feb 27

CEO

Xi Liu (62 yo)

13.5yrs

테뉴어

CN¥2,434,400

보상

Mr. Xi Liu has been General Manager and Non-Independent Director of Beijing Strong Biotechnologies, Inc. since March 2011. Mr. Liu holds Ph.D.

리더십 팀

이름	위치	테뉴어	보상	소유권
Xi Liu	GM & Non-Independent Director	13.5yrs	CN¥2.43m	11.48% CN¥ 891.3m
Wei Liu	CFO & Accounting Supervisor	13.5yrs	CN¥574.90k	0.027% CN¥ 2.1m
Sheng Dan	Deputy GM & Non-Independent Director	no data	CN¥1.81m	0.061% CN¥ 4.7m
Jian Min Wang	Secretary of the Board of Directors	9.3yrs	CN¥472.80k	0.071% CN¥ 5.5m
Qinghai Yang	Deputy General Manager	no data	데이터 없음	0.048% CN¥ 3.7m
Qixin Lin	Deputy General Manager	no data	데이터 없음	0.054% CN¥ 4.2m

13.5yrs

평균 재임 기간

47.5yo

평균 연령

경험이 풍부한 관리: 300406 의 관리팀은 노련하고 경험 (평균 재직 기간 13.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xi Liu	GM & Non-Independent Director	13.5yrs	CN¥2.43m	11.48% CN¥ 891.3m
Sheng Dan	Deputy GM & Non-Independent Director	4.1yrs	CN¥1.81m	0.061% CN¥ 4.7m
Zuojun Zou	Chairman of the Board	13.5yrs	CN¥2.43m	6.73% CN¥ 522.4m
Xiaolin Sun	Non-Independent Director	13.5yrs	데이터 없음	8.63% CN¥ 670.2m
Aiping Luo	Non-Independent Director	13.5yrs	데이터 없음	9.76% CN¥ 757.8m
Tao Jiang	Chairman of the Supervisory Committee	7.4yrs	CN¥84.00k	데이터 없음
Jian Ding	Independent Director	no data	CN¥84.00k	데이터 없음
Lei Fu	Independent Director	no data	CN¥84.00k	데이터 없음
Yonghong Chen	Independent Director	4.1yrs	CN¥84.00k	데이터 없음
Hongjun Liang	Non-Independent Director	4.1yrs	데이터 없음	데이터 없음
Xiaoya Wang	Non-Independent Director	less than a year	데이터 없음	0.080% CN¥ 6.2m
Jianping Yang	Independent Director	less than a year	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: 300406 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.

Beijing Strong BiotechnologiesInc 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Recent updates

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2023)

Is Beijing Strong BiotechnologiesInc (SZSE:300406) A Risky Investment?

Benign Growth For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Underpins Its Share Price

Beijing Strong Biotechnologies,Inc. to Report First Half, 2024 Results on Aug 23, 2024

An Intrinsic Calculation For Beijing Strong Biotechnologies,Inc. (SZSE:300406) Suggests It's 40% Undervalued

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Upcoming dividend of CN¥0.20 per share

Beijing Strong Biotechnologies,Inc. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 07 May 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Is Now The Time To Put Beijing Strong BiotechnologiesInc (SZSE:300406) On Your Watchlist?

Improved Earnings Required Before Beijing Strong Biotechnologies,Inc. (SZSE:300406) Stock's 25% Jump Looks Justified

Estimating The Fair Value Of Beijing Strong Biotechnologies,Inc. (SZSE:300406)

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Beijing Strong Biotechnologies,Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)

Beijing Strong Biotechnologies,Inc. to Report Q3, 2023 Results on Oct 25, 2023

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.11 in 2Q 2022)

New minor risk - Dividend sustainability

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 80 million worth of its shares.

Beijing Strong Biotechnologies, Inc. to Report First Half, 2023 Results on Aug 10, 2023

Beijing Strong Biotechnologies, Inc. Announces Dividend on Share A for 2022, Payable on May 22, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2021)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) signed an Equity Transfer Agreement to acquire an additional 4.45% stake in Fuzhou Maixin Biotech. Co., Ltd. from Xinyu Yuanlang Management Consulting Partnership (Limited Partnership) for approximately CNY 130 million.

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 2Q 2021)

Beijing Strong Biotechnologies, Inc. Announces Final Dividend on A Shares for the Year 2021, Payable on 27 May 2022

Beijing Strong Biotechnologies, Inc. Approves Cash Dividend for 2021

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Beijing Strong Biotechnologies, Inc. (SZSE:300406) entered into an agreement to acquire 75% stake in Wuhan Healcare Pharmaceuticals Technology Development Co., Ltd. from Xia Zhihui and Wang Ying for CNY 4 million.

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.039 in 2Q 2020)

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend for 2020, Payable on 27 May 2021

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

New 90-day low: CN¥20.29

Beijing Strong Biotechnologies, Inc. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥23.45

Third quarter earnings released

New 90-day low - CN¥19.38

First half earnings released

New 90-day high - CN¥24.20

Beijing Strong Biotechnologies, Inc. to Report First Half, 2020 Results on Aug 28, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령